40
Participants
Start Date
September 30, 2009
Primary Completion Date
June 30, 2015
Study Completion Date
June 30, 2015
rAvPAL-PEG 0.001 mg/kg
In Part 1, the planned starting dose levels is 0.001 mg/kg
rAvPAL-PEG 0.003 mg/kg
In Part 1, the planned starting dose levels is 0.003 mg/kg
rAvPAL-PEG 0.01 mg/kg
In Part 1, the planned starting dose levels is 0.01 mg/kg
rAvPAL-PEG 0.03 mg/kg
In Part 1, the planned starting dose levels is 0.03 mg/kg
rAvPAL-PEG 0.1 mg/kg
In Part 1, the planned starting dose levels is 0.1 mg/kg
Mount Sinai School of Medicine, New York
Albany Medical Center, Albany
University of Pittsburgh Medical Center, Pittsburgh
Emory Universty, Decatur
Akron Children's Hospital, Akron
University of Minnesota Medical Center-Fairview, Minneapolis
Children's Memorial Hospital, Chicago
Washington University Center for Applied Research Sciences, St Louis
The Children's Hospital, Aurora
University of Utah Hospital, Salt Lake City
Oregon Health & Science University, Portland
Lead Sponsor
BioMarin Pharmaceutical
INDUSTRY